Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

A Muulticenter, Open, Non-interventional, Retrospective Cohort Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06754865

Acronym

XYP-202401

Enrollment

1140

Registered

2025-01-01

Start date

2024-12-31

Completion date

2025-11-30

Last updated

2025-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Keywords

Acute exacerbation of chronic obstructive pulmonary disease, Xiyanping injection

Brief summary

The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to provide guidance and basis for the clinical application of Xiyanping injection combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease.The secondary objectives is to evaluate the effect of Xiyanping injection on the indicators of acute exacerbation of inflammation and symptom improvement of chronic obstructive pulmonary disease.

Interventions

DRUGXiyanping injection+ antibiotic

Xiyanping injection+ antibiotic

DRUGAntibiotic

Antibiotic

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Discharged with chronic obstructive pulmonary disease; 2. Hospitalized patients with COPD or AECOPD combined with lower respiratory tract infection; 3. The treatment course of Xiyanping injection in the exposed group was ≥3 days, and the non-exposed group did not use Xiyanping injection; 4. Study patients with complete medical records.

Exclusion criteria

1. Researchers believe that multiple proprietary Chinese medicines with the same or similar functions (such as Tanreqing injection, Reduning injection, Yanhuning injection, etc.) have been used at the same time during treatment, resulting in no assessment of efficacy or safety; 2. Patients with viral pneumonia or other systemic infection (such as urinary tract infection); 3. Patients who do not use intravenous antibiotics; 4. Refuse the case to be used by researchers.

Design outcomes

Primary

Measure	Time frame	Description
Course of intravenous antibiotics	baseline, at 3(±1), 7(±1), and 10 days during medication	Duration of intravenous antibiotic use

Contacts

Primary ContactXiyuan Hospital of China Academy of Chinese Medical Sciences

010-62835646

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026